Scalper1 News
Newly public biotech Ardelyx (ARDX) reported positive midstage trial data for its bowel-disease drug Wednesday, sending Ardelyx stock up 30.9% to 18.60 in early afternoon trading trading on the stock market today. It made its IPO in June at 14. Ardelyx said that tenapanor, which it’s developing in partnership with AstraZeneca (AZN), met its primary endpoint in a study of 371 sufferers from irritable bowel syndrome with constipation (IBS-C). After Scalper1 News
Scalper1 News